Aseptic manufacturing of lentiviral vectors

Aseptic processing methods using closed systems and sterile connections address sterility and contamination issues in lentiviral vector manufacturing, enhancing yield and reducing costs by eliminating terminal sterilization filtration.

WO2026239242A1PCT designated stage Publication Date: 2026-11-19AGC BIOLOGICS SPA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2026/054630
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-12
Filing Date
2026-05-11
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Conventional manufacturing processes for lentiviral vectors face challenges in maintaining sterility, leading to contamination risks and significant loss of viral particles due to terminal sterilization filtration, which increases complexity and costs.

Method used

Aseptic processing methods utilizing closed systems and sterile connections throughout the manufacturing process, eliminating the need for terminal sterilization filtration, by using single-use sterile components and automated systems for harvesting, clarification, purification, and formulation.

Benefits of technology

Maintains sterility and enhances yield by reducing viral particle loss, minimizing contamination risks, and lowering production costs while reducing dependency on specialized facilities.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to methods and systems for manufacturing lentiviral vectors by aseptic processing without sterilizing filtration.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] ASEPTIC MANUFACTURING OF LENTIVIRAL VECTORS

[0002] Cross-Reference to Related Applications

[0003] This Patent Application claims priority from Europan Patent Application No.

[0004] 25175798.5 filed on May 12, 2025, the entire disclosure of which is incorporated herein by reference.

[0005] Field of the Invention

[0006] The present invention relates to methods for manufacturing lentiviral vectors under aseptic conditions. More specifically, the invention provides an improved manufacturing process for lentiviral vectors that maintains sterility throughout all processing steps without terminal sterilization filtration and a manufacturing system related thereto.

[0007] Background of the Invention

[0008] Lentiviral vectors (LWs) are essential tools in gene therapy applications due to their ability to efficiently deliver genetic material into both dividing and nondividing cells. They are commonly used for ex vivo gene therapy approaches and also for in vivo gene therapy applications. Several commercially approved gene therapies utilize lentiviral vectors (LW) for gene delivery. Notable examples include Kymriah and Yescarta for blood cancers and Zynteglo for betathalassemia, Aucatzyl for r / r B-ALL, Lenmeldy™ for metachromatic leukodystrophy (MLD). In addition, many other clinical candidates are under investigation. Growing interest in the use of LWs has created a strong demand for large volumes of vectors for precl inical , toxicology and clinical studies as well as ultimately for manufacturing of drug products approved for the market.

[0009] The manufacturing of clinical-grade lentiviral vectors presents significant challenges regarding sterility, yield, and potency. To manufacture lentiviral vectors (LWs), cells such as human embryonic kidney cells (e.g., HEK293T) are introduced with 3-4 plasmids through transfection. These plasmids typically include a transfer plasmid containing the gene of interest, along with packaging plasmids carrying essential viral proteins required for gene integration and self-assembly and the plasmid carrying the envelope protein, such as vesicular stomatitis virus G protein (VSV-G). The plasmids can be transiently transfected into the cells or utilized to establish a stable producer cell line that continuously expresses all the necessary genes for LW production. As some of the gene products have a toxic effect inducible promoters (e.g., tet-off or tet-on) may be used in stable producer cell lines. By culturing transiently transfected cells or stable producer cells at suitable conditions LW are released into the cell culture supernatant through the so-called budding process. Purified lentiviral vectors are obtained by harvesting of the supernatant that is then subjected to several steps of clarification, purifications by capturing and polishing chromatography, concentration and formulation.

[0010] Conventional manufacturing processes for lentiviral vectors typically involve multiple open processing steps that increase the risk of contamination. To ensure sterility, terminal sterilizing filtration is commonly employed. However, this approach can result in significant loss of viral particles, with reported losses ranging from 30% to over 70% of functional vector particles during terminal filtration steps. Such losses substantially impact manufacturing efficiency and increase production costs.

[0011] Additionally, traditional open processing methods require specialized cleanroom facilities with extensive environmental monitoring, increasing manufacturing complexity and costs.

[0012] There remains a need in the art for improved methods for manufacturing lentiviral vectors that maintain aseptic conditions throughout the process, eliminate the need for terminal sterilization filtration, and provide high-quality vectors suitable for clinical applications.

[0013] Summary of the Invention

[0014] The present invention addresses the limitations of conventional manufacturing processes by providing a method for manufacturing lentiviral vectors through a complete aseptic processing approach. The method utilizes closed systems and sterile connections throughout the entire manufacturing process, eliminating the need for terminal sterile filtration while maintaining product sterility.In one aspect, the invention provides a method for manufacturing lentiviral vectors comprising: producing lentiviral vectors in a closed sterile cell culture unit; harvesting cell culture supernatant containing said lentiviral vectors into a first sterile collection container; clarifying said supernatant through sterile filters; collecting clarified supernatant in a second sterile collection container; purifying said lentiviral vectors using anion exchange chromatography in an automated system operated with a sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane; and formulating said lentiviral vectors by diafiltration using an automated system comprising single-use sterile components. Importantly, all fluid transfers operated between steps and in each step are conducted through sterile connections to maintain aseptic conditions throughout the manufacturing process.

[0015] In another aspect the present invention addresses a system for manufacturing lentiviral vectors by aseptic processing comprising: a closed sterile cell culture unit configured to produce lentiviral vectors; a first sterile collection container fluidically connected to the cell culture unit via sterile tubing for harvesting cell culture supernatant; a clarification module comprising a series of sterile filters arranged in decreasing pore size fluidically connected to the first sterile collection container via sterile tubing and sterile connections, a second sterile collection container fluidically connected to the clarification module; a clarification module comprising an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology; an automated sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane configured for purifying the lentiviral vectors; an automated tangential flow filtration unit comprising singleuse sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafiltration to formulate the lentiviral vectors; a sterile connection network connecting all components of the system to maintain aseptic conditions throughout the manufacturing process; and optionally a control system configured to monitor and regulate the operation of the system components.In another aspect, the invention provides a method for manufacturing lentiviral vectors comprising: producing lentiviral vectors in a closed sterile cell culture unit; simultaneously harvesting and clarifying supernatant containing said lentiviral vectors by filtering the cell culture supernatant through an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology; collecting the clarified supernatant in a sterile container; purifying said lentiviral vectors using anion exchange chromatography in an automated system operated with a sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane; and formulating said lentiviral vectors by diaf iltration using an automated system comprising single-use sterile components. Importantly, all fluid transfers operated between steps and in each step are conducted through sterile connections to maintain aseptic conditions throughout the manufacturing process.

[0016] In another aspect, the present invention provides a system for manufacturing lentiviral vectors by aseptic processing, the system comprising: a closed sterile cell culture unit configured to produce lentiviral vectors; a clarification module comprising an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology; a sterile collection container fluidically connected to the clarification module to collect clarified supernatant; an automated sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane fluidically connected to the sterile collection container and configured for purifying the lentiviral vectors; an automated tangential flow filtration unit comprising single-use sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafiltration to formulate the lentiviral vectors; a sterile connection network connecting all components of the system to maintain aseptic conditions throughout the manufacturing process; and optionally a control system configured to monitor and regulate the operation of the system components.A key advantage of the invention is that it does not require a terminal sterilizing filtration step, which typically results in significant loss of viral particles. Instead, sterility is maintained throughout the entire process through the use of closed systems and sterile connections.

[0017] Detailed Description of the Invention

[0018] Definitions

[0019] For the purpose of clarity and to facilitate understanding of the invention, the following definitions are provided for terms used throughout this specification. These definitions are intended to provide context for interpreting the claims and should not be construed as limiting the scope of the invention.

[0020] "Aseptic processing" refers to a manufacturing technique performed in a manner that prevents contamination by microorganisms. It involves the handling of sterile materials in such a way that sterility is maintained throughout the process. In the context of this invention, aseptic processing means that all manufacturing steps are conducted using sterile equipment, components, and connections, without introducing environmental contaminants.

[0021] "Automated system" refers to equipment that performs operations with minimal manual intervention, controlled by programmed instructions. In the context of this invention, this includes chromatography systems such as AKTA™ systems from Cytiva, BioProcess™ systems from Sartorius, or BioSC™ systems from Novasep. It also encompasses automated filtration systems for tangential flow filtration (TFF) such as Cogent® M TFF systems from Millipore Sigma, KrosFlo® KR2i or KMPi TFF systems from Repligen, Cadence™ Automated TFF systems from Pall, or AKTA™ flux S / P systems from Cytiva.

[0022] "Cell culture supernatant" refers to the liquid medium surrounding cells in a culture system, which contains secreted products such as lentiviral vectors, proteins, and other biomolecules. According to the present invention the supernatant is harvested after the cells have been cultured under conditions suitable for lentiviral vector production.

[0023] "Clarification filters" refers to filtration devices used to remove cells, cell debris, and other particulates from cell culture harvests including i) planar filters orsurface filters, that is thin, membrane-based filters with a defined pore size that act as a mechanical sieve; commercial examples of this kind of filters include but are not limited to Durapore® PVDF membranes (Merck) Supor® PES membranes (Pall) Sartopore® 2 (Sartorius); ii) Depth Filters, that is filters that utilize a thick, porous medium (typically cellulose, diatomaceous earth, or charged resins) to trap contaminants throughout the entire tortuous path; commercial examples include but are not limited to Millistak+® pods from Millipore Sigma, Supracap™ capsules from Pall, Sartoclear® filters from Sartorius, or POD® filters from Parker, available in various pore sizes typically ranging from 0.45 pm to 1.5 pm; iii) Tangential Flow Filtration (TFF) filters, that is filters wherein the fluid flows parallel to the membrane surface; commercial examples include Pellicon® Cassettes (Merck) - Planar TFF Sartocon® Cassettes (Sartorius) - Planar TFF Centramate® I T-Series (Pall) - Planar TFF Xampler™ I ReadyToProcess (Cytiva) - Hollow Fiber TFF: or iv) hybrid filters that combine any of the filtration technology above, including combination of tangential flow filtration technology and depth filtration technology, a commercially available example is TFDF® (Repligen).

[0024] "Closed sterile cell culture device" or “Closed sterile cell culture unit” refers to a bioreactor or similar vessel designed to maintain a sterile environment for cell culture without exposure to the external environment during operation. Examples include, but are not limited to, fixed-bed bioreactors, stirred-tank bioreactors, wave bioreactors, hollow fiber bioreactors, packed-bed bioreactors (such as iCELLis® systems from Pall Corporation), perfusion bioreactors, single-use bioreactor bags (such as WAVE™ bioreactors from Cytiva), microcarrier culture systems, and combinations thereof.

[0025] "Fluid": refers to any liquid or gas that can flow and is used in the context of the manufacturing process. In this invention, fluid specifically refers to liquids including cell culture media, buffers, solutions, clarified supernatant, and formulated lentiviral vector solutions that are transferred between the several components used to perform the method according to the present invention. "Diafiltration" refers to a membrane-based separation technique that uses buffer exchange to replace the original solution with a different buffer while retaining theproduct of interest. It uses the same equipment as ultrafiltration but involves the addition of new buffer as filtrate is removed. Commercial options include Cogent® TFF systems from Millipore Sigma, AKTA™ flux systems from Cytiva, or KrosFlo® systems from Repligen, with single-use kits such as Pellicon® cassettes (Millipore Sigma), Hollow Fiber cartridges (Repligen), or ReadyToProcess™ filters (Cytiva).

[0026] "Single-use sterile components" refers to pre-sterilized disposable parts that are used once and then discarded, eliminating the need for cleaning and resterilization. These include but are not limited to bags, tubing, connectors, sensors, filters, and chromatography devices designed for one-time use in biopharmaceutical manufacturing.

[0027] "Sterile" refers to the state of being free from viable microorganisms, including bacteria, fungi, viruses, and spores. In the context of this invention, components, containers, and systems described as "sterile" have been subjected to validated sterilization processes to ensure the absence of viable microorganisms. Sterilization methods can be broadly categorized as heat, chemical, radiation, and filtration.

[0028] "Sterile connection" refers to a means of connecting two sterile fluid pathways while maintaining the sterility of both. Sterile connections are specialized systems or devices designed to enable the transfer of materials (such as liquids, gases, or solids) between two environments while maintaining sterility and preventing contamination. This may include aseptic connectors (such as Pall's Kleenpak™ connectors or Cytiva's ReadyMate™ connectors), sterile tubing welders, or other validated aseptic connection technologies. Sterile connections are essential in industries and applications where maintaining a sterile environment is critical, such as medicine, pharmaceuticals, and biotechnology. Key features of sterile connections include: a) sterility assurance they are engineered to ensure complete sterility during the transfer process, preventing the introduction of microorganisms or unwanted particles, b) durable materials they are made from materials that can withstand sterilization methods like autoclaving, gamma irradiation, or chemical sterilization, c) ease of use they are designed for easy connection and disconnection without compromising sterility, d) they can besingle use or reusable depending on the application, they can be disposable to minimize contamination risks or reusable with proper sterilization protocols. There are several types of sterile connections: 1) sterile quick connectors that allow fast and secure connections between tubing or systems without contamination, 2) aseptic transfer systems used for transferring liquids or materials between sterile containers, 3) single-use connections often preferred for critical applications to reduce contamination risks and simplify processes. "Ultrafiltration" refers to a separation process using membranes with specific molecular weight cut-offs to concentrate solutions by removing water and small solutes while retaining larger molecules like viral vectors. Commercial systems include Cogent® TFF systems from Millipore Sigma, AKTA™ flux from Cytiva, or KrosFlo® systems from Repligen, with single-use kits such as Pellicon® cassettes (Millipore Sigma), Hollow Fiber cartridges (Repligen), or ReadyToProcess™ filters (Cytiva).

[0029] Method for Manufacturing Lentiviral Vectors

[0030] The present invention provides a comprehensive method for the aseptic manufacturing of lentiviral vectors suitable for clinical applications. Each aspect of the invention will now be described in detail.

[0031] Lentiviral vectors (LWs)

[0032] The present invention relates to the manufacturing of LWs. LWs are gene delivery vehicles derived from lentiviruses. A detailed list of lentiviruses may be found in Coffin et al (“Retroviruses” 1997 Cold Spring Harbour Laboratory Press Eds: JM Coffin, SM Hughes, HE Varmus pp 758-763). In brief, lentiviruses can be divided into primate and non-primate groups. Examples of primate lentiviruses include, but are not limited to: the human immunodeficiency virus (HIV), the causative agent of human acquired-immunodeficiency syndrome (AIDS), and the simian immunodeficiency virus (SIV). The non-primate lentiviral group includes the prototype “slow virus” visna / maedi virus (VMV), as well as the related caprine arthritis-encephalitis virus (CAEV), equine infectious anaemia virus (EIAV) and the more recently described feline immunodeficiency virus (FIV) and bovine immunodeficiency virus (BIV).In a preferred embodiment, the lentiviral vector is derived from an HIV lentivirus, more preferably the lentiviral vector is derived from an HIV-1 lentivirus.

[0033] An exemplary lentiviral vector to be used in the method of the invention comprises at least the following portion of lentiviral genome: a) a 5' long terminal repeat (LTR); b) the packaging sequence psi; c) a Rev Response Element (RRE); d) a promoter operably linked to a gene of interest; e) a 3’ long terminal repeat (LTR). In a preferred embodiment the U3 region of the 5' LTR is replaced with a heterologous promoter selected from the group consisting of: a cytomegalovirus (CMV) promoter, a Rous Sarcoma Virus (RSV) promoter, or a Simian Virus 40 (SV40); thus rendering lentiviral transcription tat independent. In a further preferred embodiment, the 3’ LTR sequence contains a deletion of the U3 region (i.e. the vector is a self-inactivating vector or SIN vector). The lentiviral vector may further comprise a lentiviral central poly-purine tract (cPPT) and Woodchuck Hepatitis Virus (WHP) Posttranscriptional Regulatory Element (WPRE).

[0034] Cells

[0035] Lentiviral vectors can be suitably propagated in cells (sometimes referred to as "host cells'). All cell lines suitable for the manufacturing of viral vectors can be used in the present invention. In one embodiment the packaging cell line to be used in the present invention is selected from HEK293, HEK293 T, HEK 293E, HEK 293FT, 293 Vec, TE671, HT1080 or HeLa cell line. In a preferred embodiment the packaging cell line is HEK 293 T.

[0036] Production

[0037] The first step in the method involves producing lentiviral vectors in a closed sterile cell culture unit. The closed sterile cell culture unit may be selected from the group consisting of a fixed-bed bioreactor, a stirred-tank bioreactor, a wave bioreactor, a hollow fiber bioreactor, a packed-bed bioreactor, a perfusion bioreactor, a single-use bioreactor bag, a microcamer culture system, and combinations thereof. In a preferred embodiment, the closed sterile cell culture unit is a singleuse packed-bed bioreactor.

[0038] The production of lentiviral vectors in the closed sterile cell culture unit can be accomplished through several approaches.According to one embodiment LVVs are produced in the cell culture device by plasmid DNA transient transfection of cells i.e. in the method of the invention at least two expression plasmids carrying two different genes are transiently cotransfected into a cell line (also called packaging cell line). According to a preferred aspect of the invention, the cells are co-transfected at least with: a packaging plasmid carrying lentiviral Gag / Pol genes, a plasmid carrying the gene encoding the envelope protein of interest and the transfer plasmid carrying the essential lentiviral genome elements, as disclosed above, and the gene of interest. In another preferred embodiment the lentiviral regulatory protein Rev may be further expressed in trans on a fourth separate plasmid. In a further aspect of the invention lentiviral protein tat may be further expressed on a fifth separate plasmid. Examples of suitable env genes include, but are not limited to, VSV-G env, MLV 4070 env, RD114 env, RD114-TR, RD114pro, baculovirus 5 GP64 env, GALV or envelope proteins derived from Measle virus. In a preferred embodiment, in the method of the invention the multi-plasmid DNA transfection is performed using a third generation LVVs viral vector system composed of four plasmids i.e.: one plasmid carrying the lentiviral gag / pol genes, one plasmid carrying lentiviral rev gene, one plasmid carrying the gene encoding the envelope protein, preferably the gene encoding the VSV-G envelope protein, and one plasmid carrying the transfer vector including the required portion of the lentiviral genome and the foreign gene of interest. In a preferred embodiment the method of the invention comprises inoculating cells into the closed sterile cell culture unit; culturing said cells for expansion for at least one day; transfecting the cells; and cultivating the cells for at least 24 hours after transfection. All steps are performed using sterile containers and sterile connections to operate transfer of fluids to maintain aseptic conditions.

[0039] In another embodiment lentiviral vectors can be produced by inoculating into the closed sterile cell culture unit stable packaging cells capable of constitutively expressing lentiviral gag / pol, rev and VSV-G env for expansion culturing such stable packaging cells for at least one day in the sterile cell culture device; transfecting the cells with the transfer vector plasmid only; and cultivating the cells for at least 24 hours after transfection.In another embodiment, lentiviral vectors can be produced by culturing a stable producer cell line capable of constitutively expressing all lentiviral vector components and the gene of interest in said closed sterile cell culture unit under conditions suitable for lentiviral vector production.

[0040] According to the present invention the inoculum of the cells and transfection of the cells are performed in a sterile manner using sterile components and sterile connections for the transfer of fluids required to perform such steps of the method.

[0041] The skilled man may use any of the cell cultivation operating conditions known in the art and applicable to the closed sterile cell culture unit in use for supplying the cell culture medium containing nutrients to the cells. For example, the iCELLis® Single-Use Fixed-Bed Bioreactor Systems allows to operate cell culturing in three different modes: 1) “in batch mode” according to which the cells are cultivated using a constant volume of cell culture medium into the bioreactor for the required period of time up to the media consumption (i.e.: the exhaustion of the nutrients required for cell growth and the accumulation of cell metabolites) and, upon reaching medium consumption, it is necessary to drain completely the exhausted medium from the bioreactor and fill it with the fresh medium 2) “in perfusion mode” according to which during the cell culture, the fresh medium is added into the bioreactor at a constant flow rate and the exhausted medium is removed at the same flow rate to be wasted or harvested, while maintaining a constant total volume of cell culture medium into the bioreactor and allowing a constant supply of nutrients to the cell culture and a constant removal of cell metabolites; 3) “recirculation mode” according to which the cells are cultivated in a constant amount of cell culture medium into the bioreactor, which is connected with an external container serving as reservoir of medium, from which additional culture medium is added at a constant flow rate into the bioreactor (as in perfusion mode) and removed at the same flow rate to be carried back to the reservoir. The culture in re-circulation mode allows an increase of the total volume of medium used for the cell culture. Each of the above-mentioned operational modes or a combination thereof may be employed in the method of the invention to culture the cells for expansion.Harvesting and Clarification

[0042] Following the production phase, the cell culture supernatant containing the lentiviral vectors is harvested into a first sterile container. The harvested supernatant is then subjected to a clarification step to remove cellular debris and large particulates.

[0043] The clarification step comprises sequentially passing the cell culture supernatant through at least two sterile filters of decreasing pore size. All sterilizable filters available on the market can be used in the method of the invention. This sequential filtration approach ensures efficient removal of cellular debris while minimizing loss of viral particles. In one embodiment the maximum pore size of the filters employed in the invention is 1.5pm. In another embodiment the minimum pore size of the filters is 0.45pm. In a preferred embodiment, the clarification step comprises sequentially passing the cell culture supernatant through at least one sterile filter having pore size of 1 ,5pm and at least one filter having 0.45pm. In another embodiment clarification step comprises passing the cell culture supernatant through at least one or more sterile depth filter. In a further embodiment the clarification step comprises filtering the cell culture supernatant thorough a sterile TFF filter or, preferably, a sterile hybrid filter combining tangential flow filtration technology and depth filtration technology. The clarified supernatant is collected in a second sterile container through a sterile connection.

[0044] In another embodiment of the invention, the steps of harvesting and clarifying the cell culture supernatant are performed simultaneously and the clarification is carried out by filtering the cell culture supernatant using an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology, preferably hybrid filters. In this embodiment, the closed sterile cell culture unit is fluidically connected via sterile connections to the clarification module, and the clarified supernatant, free of cells and large debris, is then collected directly into a sterile collection container. In this specific embodiment, the step of harvesting the bulk supernatant into a "first sterile collection container" prior to clarification is not required, as harvesting andclarification are consolidated into a single, continuous or semi-continuous operation.

[0045] Concentration

[0046] Optionally, in some embodiments, before anion exchange chromatography, the clarified supernatant may be concentrated, to obtain a concentrated lentiviral vector preparation, by ultrafiltration using an automated tangential flow filtration system comprising single-use sterile components. Several examples of automated systems to operate tangential flow filtration are available on the market and may be used to practice the present invention including Cogent® M TFF systems from Millipore Sigma, KrosFlo® KR2i or KMPi TFF systems from Repligen, Cadence™ Automated TFF systems from Pall, or AKTA™ Readyflux and flux S / P systems from Cytiva, which can be used for concentration and diafiltration operations in an aseptic manner using single-use flow paths and filters.

[0047] In the method of the present invention, ultrafiltration can be performed using sterile single use ultrafiltration cartridges and hollow fiber systems. In a preferred embodiment, ultrafiltration is performed using sterile single use hollow fiber filters. More preferably the sterile single use hollow fiber filter has a molecular weight cut-off between 100 kDa and 750 kDa. The concentrated clarified supernatant is collected in a sterile container. This concentration step helps to reduce the volume of material to be processed in subsequent purification steps and at the same time reduces the amount of contaminating molecules smaller than the hollow-fiber pore-size

[0048] Purification

[0049] According to the method of the invention, lentiviral vectors are purified by anion exchange chromatography in an automated system comprising single-use sterile components. Several examples of automated system to operate chromatography are available on the market and may be used to practice the present invention including AKTA™ systems from Cytiva, BioProcess™ systems from Sartorius, or BioSC™ systems from Novasep, which can be configured with single-use flow paths for aseptic operation. The purification step is operated with a sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane. In a preferred embodiment, the chromatographic membrane is functionalized with a quaternary amine. This purification step allows for the selective capture of lentiviral vectors while removing process-related impurities. In an embodiment, the membrane-based anion exchange chromatography units suitable for the present invention are preferably macroporous membrane adsorbers. In such systems, the large, interconnected pores of the membrane allow for mass transport to be dominated by convection, rather than diffusion. In another preferred embodiment, the chromatographic membrane is functionalized with a weak anion exchange ligand. A non-limiting example of a suitable weak anion exchange ligand is diethylaminoethyl (DEAE). Weak anion exchangers offer different selectivity compared to strong exchangers and allow for elution under milder conditions, which can be beneficial for preserving the infectivity of sensitive viral vectors. A commercial example of a sterile, single-use membrane adsorber utilizing a weak anion exchange ligand and designed for convective flow is the Sartorius Convec® D membrane.

[0050] Therefore, the purification step can be optimized by selecting either a strong or a weak membrane-based anion exchanger to achieve the desired purity and yield for the specific lentiviral vector being manufactured.

[0051] Post-Purification Concentration

[0052] In some embodiments, optionally the method further comprises concentrating the lentiviral vectors by ultrafiltration using an automated system comprising singleuse sterile components after purification and before formulation.

[0053] Formulation

[0054] The final step in the method involves formulating the lentiviral vectors by diafiltration using an automated system comprising single-use sterile components. The formulation step is operated with a single-use sterile hollow fiber filter. This step allows for buffer exchange to place the lentiviral vectors in an appropriate final formulation buffer suitable for the intended application.

[0055] Maintaining Aseptic ConditionsA key aspect of the invention is that all components used for the process are sterile, and those components in direct contact with the cells or the lentiviral vectors are in a preferred configuration of the invention single use. In addition, throughout the method of the invention, fluid transfers operated between steps and during each step are conducted through sterile connections to maintain aseptic conditions throughout the manufacturing process. This eliminates the need for terminal sterilization filtration of the formulated lentiviral vectors, which can result in significant loss of viral particles.

[0056] System

[0057] According to another aspect of the present invention, it is provided a system for manufacturing lentiviral vectors by aseptic processing comprising:

[0058] 1. A closed sterile cell culture unit configured to produce lentiviral vectors;

[0059] 2. A first sterile collection container fluidically connected to the cell culture unit via sterile tubing for harvesting cell culture supernatant;

[0060] 3. A clarification module comprising a series of sterile filters arranged in decreasing pore size in order to obtain a concentrated lentiviral vector preparation fluidically connected to the sterile collection container via sterile tubing and sterile connections or an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology;

[0061] 4. A second sterile collection container fluidically connected to the clarification module;

[0062] 5. An automated anion exchange chromatography unit comprising a chromatographic membrane configured for purifying the lentiviral vectors;

[0063] 6. At least one automated tangential flow filtration unit comprising single-use sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafi Itration to formulate the lentiviral vectors; 7. A sterile connection network connecting all components of the system to maintain aseptic conditions throughout the manufacturing process; andThe operations of the system are monitored and controlled through control systems commonly known in the art.

[0064] In another preferred configuration of the system, designed for integrated harvesting and clarification, the system comprises:

[0065] 1. A closed sterile cell culture unit;

[0066] 2. A clarification module comprising an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology

[0067] 3. A sterile collection container fluidically connected to the clarification module to collect clarified supernatant;

[0068] 4. An automated sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane , fluidically connected to the sterile collection container and configured for purifying the lentiviral vectors;

[0069] 5. At least one automated tangential flow filtration unit comprising single-use sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafi Itration to formulate the lentiviral vectors; 6. A sterile connection network connecting all components of the system to maintain aseptic conditions throughout the manufacturing process; and

[0070] The operations of the system are monitored and controlled through control systems commonly known in the art.

[0071] In this configuration, the first sterile collection container and the separate clarification module with filters of the previous embodiment are replaced by the automated system using single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology.

[0072] In a preferred embodiment of the systems according to the present invention, the closed sterile cell culture unit of the invention is a bioreactor selected from the group consisting of a fixed-bed bioreactor, a stirred-tank bioreactor, a wavebioreactor, a hollow fiber bioreactor, a packed-bed bioreactor, a perfusion bioreactor, a single-use bioreactor bag, a microcarrier culture system, and combinations thereof. In a preferred embodiment of the system according to the invention, the closed sterile cell culture unit is a single-use packed-bed bioreactor. Such bioreactor is configured to maintain sterility throughout the cell culture period including means for sterile addition and collection of fluids configured to perform manufacturing of lentiviral vectors such as cell inoculation, cell culture medium, supply of reagents including transfection reagents and sterile sampling, a temperature control system, a pH monitoring system and a dissolved oxygen monitoring system. In a preferred embodiment of the invention, the bioreactor is configured to be operated to perform multiple types of manufacturing processes including batch, fed-batch, perfusion, fill and draw, or recirculation processes or a combination thereof. Alternatively, the closed sterile cell culture unit is preferably a stirred-tank bioreactor.

[0073] In a preferred embodiment, the clarification module of the system comprises at least two sterile filters arranged in sequence of decreasing pore size. In one preferred embodiment, such filters have maximum pore size of 1.5 pm. In another preferred embodiment such filters have minimum pore size of 0.45 pm. In a particularly preferred embodiment, the clarification module of the system comprises at least two sterile filters arranged in sequence of decreasing pore size wherein the maximum pore size is 1.5 pm and the minimum pore size is 0.45 pm. In an alternative preferred embodiment, the clarification module of the system comprises an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile TFF filters or sterile hybrid filters combining tangential flow filtration technology and depth filtration technology. In one embodiment the anion exchange chromatography unit of the system comprises a sterile single-use membrane-based anion exchange chromatography device, an automated buffer management system for loading, washing, and elution operations, single-use sterile tubing, sterile kits and sterile connections for transfer of fluids configurated to maintain sterility throughout the purification process. In a particularly preferred embodiment, the single-usemembrane-based anion exchange chromatography unit comprises chromatographic membrane functionalized with a quaternary amine.

[0074] In one embodiment the tangential flow filtration unit of the system comprises an automated buffer management system for performing ultrafiltration and / or diafiltration, a single-use sterile device selected from an ultrafiltration cartridge or an hollow fiber filter, a single-use sterile tubing, sterile kits and sterile connections for transfer of fluids configurated to maintain sterility throughout the ultrafiltration process and / or diafiltration process. More preferably, the tangential flow filtration unit of the system comprises a single use sterile hollow fiber filter.

[0075] The system of the invention comprises one or more integrated control systems configured to monitor and control all process parameters, perform automated fluid transfers between system components, maintain records of process parameters for quality assurance, alert operators of any deviations from set parameters; and control maintenance of aseptic conditions throughout the process. These control systems are commonly known in the art.

[0076] The method of the present invention offers several advantages over conventional manufacturing processes for lentiviral vectors:

[0077] 1. Elimination of terminal sterilization filtration, resulting in higher yields of functional viral particles

[0078] 2. Reduced risk of contamination through the use of closed systems and sterile connections

[0079] 3. Increased process scalability through the use of automated systems and single-use components

[0080] 4. Improved reproducibility through standardized processing

[0081] 5. Reduced dependency on specialized cleanroom facilities

[0082] 6. Lower process development and validation costs

[0083] 7. Greater flexibility and faster turnaround times for manufacturing EXAMPLES

[0084] Example 1 : Production of Lentiviral Vectors Using Transient TransfectionHEK293T cells were inoculated into a single-use packed-bed bioreactor iCellis Nano at a density of 5000cells / cm2. The cells were cultured at 37°C and 5% CO2 for for three days. Transfection was performed using a mixture of four plasmids (transfer vector, packaging plasmid, Rev-expressing plasmid, and envelope plasmid) complexed with polyethylenimine (PEI). The transfection mixture was added to the bioreactor through a sterile connection.

[0085] The cells were cultured for an additional 39 hours post-transfection. The cell culture supernatant was harvested into a sterile container using a sterile peristaltic pump and sterile tubing assembly. The harvested supernatant was clarified by sequential filtration through a 1.5pm filter followed by a 0.45pm filter using sterile connections between each filtration step.

[0086] Supernatant was purified through a chromatographic purification step using a capsule containing a sterile Cytiva Mustang Q membrane (strong ion exchange - quaternary amine) connected to an AKTA ready system through a sterile, single use flow path. The clarified supernatant was applied onto the chromatographic membrane through single-use sterile flow paths and connections, taking advantage of an automated method. After loading was completed, elution of the lentiviral vectors bound to the resin was obtained with NaCI containing D-PBS buffers. The eluted lentiviral vector was immediately diluted with D-PBS to reduce salt concentration. Around 50-60% of the applied lentiviral vectors was recovered in the eluted peak, in terms of infectious viral titre, a performance similar or better than standard nonsterile resins. Residual host cell proteins and total DNA removal was similarly comparable or better than what obtained with standard non-sterile resin.

[0087] The purified lentiviral vectors were then subjected to a following step for further concentration and formulated by diafiltration into a final formulation buffer. This was obtained using a 750 kDa sterile hollow fiber, connected via sterile flow path and aseptic connectors to an automated TFF system with single use flow path. After a concentration phase, final formulation medium was progressively added through sterile connections to execute the diafiltration step and formulate the lentiviral vectors.As all the purification and concentration steps were executed in a close system, with sterile connectors and with sterile components, there was no need to execute any final sterilizing filtration. As the filtration step has a significative impact on overall LVV recovery, with losses up to 70-80%, the possibility to avoid this step resulted in an overall much higher process recovery.

Claims

CLAIMS1. A method for manufacturing lentiviral vectors by aseptic processing comprising:a. producing lentiviral vectors in a closed sterile cell culture unit;b. harvesting cell culture supernatant containing said lentiviral vectors into a first sterile collection container;c. clarifying said supernatant through sterile filters;d. collecting clarified supernatant in a second sterile collection container; e. purifying said lentiviral vectors using anion exchange chromatography in an automated system operated with a sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane; andf. formulating said lentiviral vectors by diafiltration using an automated system comprising single-use sterile components;wherein all fluid transfers operated between steps and in each step are conducted through sterile connections to maintain aseptic conditions throughout the manufacturing process and wherein the method does not comprise a step of sterilizing filtration of the formulated lentiviral vectors.

2. The method according to claim 1, further comprising a step of concentrating said lentiviral vectors by ultrafiltration using an automated system comprising single-use sterile components after step e and before step f.

3. The method according to anyone of claims 1 or 2, further comprising concentrating the clarified supernatant by ultrafiltration using an automated tangential flow filtration system comprising single-use sterile components after step d and before step e, wherein the concentrated clarified supernatant is collected in a further sterile container.

4. The method according to claims 1 to 3, wherein producing lentiviral vectors in the closed sterile cell culture device comprises:i. inoculating cells into the closed sterile cell culture unit;ii. culturing said cells for expansion for at least one day;iii. transfecting said cells; andiv. cultivating the cells for at least 24 hours after transfection;wherein all steps from i to iv are performed using sterile containers and sterile connections to operate transfer of fluids to maintain aseptic conditions.

5. The method according to claims 1 to 4, wherein producing lentiviral vectors in step a. comprises culturing a stable producer cell line capable of constitutively expressing lentiviral vector components in said closed sterile cell culture unit under conditions suitable for lentiviral vector production.

6. The method according to any preceding claims, wherein the clarification step c. comprises sequentially passing the cell culture supernatant through at least two sterile filters of decreasing pore size to remove cellular debris and large particulates from viral vector preparation.

7. The method according to claim 6, wherein the minimum pore size of the filter is 0.45 mm.

8. The method according to claim 6 or 7, wherein the maximum pore size of the filter is 1.5 mm.

9. The method according to claim 1 to 5, wherein the clarification step c. comprises filtering the cell culture supernatant through a sterile hybrid filter combining tangential flow filtration technology and depth filtration technology.

10. The method according to claim 1 to 9, wherein the chromatographic membrane is functionalized with a quaternary amine.

11. The method according to claims 1 to 10, wherein the chromatographic membrane is functionalized with a weak anion exchange ligand.

12. The method according to claim 11, wherein the weak anion exchange ligand is diethylaminoethyl (DEAE).

13. The method according to any of preceding claims, wherein the formulation step f. is operated with a single-use sterile hollow fiber filter.

14. The method according to anyone of claims from 2 to 13, wherein the concentration step is operated with a single-use sterile hollow fiber filter.

15. A system for manufacturing lentiviral vectors by aseptic processing comprising:- a closed sterile cell culture unit configured to produce lentiviral vectors; - a first sterile collection container fluidically connected to the cell culture unit via sterile tubing for harvesting cell culture supernatant;- a clarification module comprising a series of sterile filters arranged in decreasing pore size in order to obtain a concentrated lentiviral vector preparation, fluidically connected to the first sterile collection container via sterile tubing and sterile connections;- a second sterile collection container fluidically connected to the clarification module;- an automated sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane configured for purifying the lentiviral vectors;- at least one automated tangential flow filtration unit comprising single-use sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafiltration to formulate the lentiviral vectors; and- a sterile connection network connecting all components of the system to maintain aseptic conditions.

16. The system according to claim 15, wherein the closed sterile cell culture unit is selected from the group consisting of a fixed-bed bioreactor, a stirred-tank bioreactor, a wave bioreactor, a hollow fiber bioreactor, a packed-bed bioreactor, a perfusion bioreactor, a single-use bioreactor bag, a microcarrier culture system, and combinations thereof.

17. The system according to claim 16, wherein the closed sterile cell culture unit is a single use packed-bed bioreactor.

18. A method for manufacturing lentiviral vectors by aseptic processing, the method comprising:a. producing lentiviral vectors in a closed sterile cell culture unit;b. simultaneously harvesting and clarifying cell culture supernatant containing said lentiviral vectors by filtering the cell culture supernatant thorough a sterile hybrid filter combining tangential flow filtration technology and depth filtration technology;c. collecting the clarified supernatant in a sterile container;d. purifying said lentiviral vectors from the clarified supernatant using anion exchange chromatography in an automated system operated with a sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane; ande. formulating said lentiviral vectors by diafiltration using an automated system comprising single-use sterile components;wherein all fluid transfers between and during said steps are conducted through sterile connections to maintain aseptic conditions throughout the manufacturing process and wherein the method does not comprise a step of sterilizing filtration of the formulated lentiviral vectors.

19. The method according to claim 18, wherein producing lentiviral vectors in in the closed sterile cell culture device comprises:i. inoculating cells into the closed sterile cell culture unit;ii. culturing said cells for expansion for at least one day;iii. transfecting said cells; andiv. cultivating the cells for at least 24 hours after transfection;wherein all steps from i to iv are performed using sterile containers and sterile connections to operate transfer of fluids to maintain aseptic conditions.

20. The method according to claims 18 or 19, wherein producing lentiviral vectors in step a. comprises culturing a stable producer cell line capable of constitutively expressing lentiviral vector components in said closed sterile cell culture unit under conditions suitable for lentiviral vector production.

21. The method according to claims 18 to 20, wherein the chromatographic membrane is functionalized with a quaternary amine.

22. The method according to claims 18 to 21, wherein the chromatographic membrane is functionalized with a weak anion exchange ligand.

23. The method according to claim 22, wherein the weak anion exchange ligand is diethylaminoethyl (DEAE).

24. The method according to claims 18 to 23, wherein the formulation step e. is performed using a single-use sterile hollow fiber filter.

25. The method according to any of claim 18 to 24, further comprising a step of concentrating said lentiviral vectors by ultrafiltration using an automated system comprising single-use sterile components after the purification of step d. and before the formulation of step e.

26. The method according to anyone of claims 18 to 25, further comprising concentrating the clarified supernatant by ultrafiltration using an automated tangential flow filtration system comprising single-use sterile components after step c and before step d, wherein the concentrated clarified supernatant is collected in a further sterile container.

27. A system for manufacturing lentiviral vectors by aseptic processing, the system comprising:- a closed sterile cell culture unit configured to produce lentiviral vectors; - a clarification module comprising an automated system that performs operations in an aseptic manner using sterile single-use flow paths and sterile hybrid filters combining tangential flow filtration technology and depth filtration technology;- a sterile collection container fluidically connected to the clarification module to collect clarified supernatant;- an automated sterile single-use membrane-based anion exchange chromatography unit comprising a chromatographic membrane, fluidically connected to the sterile collection container and configured for purifying the lentiviral vectors;- at least one automated tangential flow filtration unit comprising single-use sterile components configured for performing ultrafiltration to concentrate purified lentiviral vector preparation and / or diafiltration to formulate the lentiviral vectors; and- a sterile connection network connecting all components of the system to maintain aseptic conditions.

28. The system according to claim 27, wherein the closed sterile cell culture unit is selected from the group consisting of a fixed-bed bioreactor, a stirred-tank bioreactor, a wave bioreactor, a hollow fiber bioreactor, a packed-bed bioreactor, a perfusion bioreactor, a single-use bioreactor bag, a microcarrier culture system, and combinations thereof.

29. The system according to claim 28, wherein the closed sterile cell culture unit is a stirred-tank bioreactor.